Prescription opioid characteristics at initiation for non-cancer pain and risk of treated opioid use disorder: A population-based study

被引:6
|
作者
Papadomanolakis-Pakis, Nicholas [1 ,2 ]
Moore, Kieran M. [1 ,2 ]
Peng, Yingwei [1 ]
Gomes, Tara [3 ,4 ]
机构
[1] Queens Univ, Dept Publ Hlth Sci, 62 Fifth Field Co Lane, Kingston, ON K7L 3N6, Canada
[2] KFL&A Publ Hlth, 221 Portsmouth Ave, Kingston, ON K7M 1V5, Canada
[3] St Michaels Hosp, Li Ka Shing Knowledge Inst, 209 Victoria St, Toronto, ON M5B 1T8, Canada
[4] Univ Toronto, ICES, 155 Coll St, Toronto, ON M5T 1P8, Canada
关键词
Addiction; Opioid analgesics; Opioids; Opioid use disorder; Non-cancer pain; Pharmacoepidemiology; THERAPY; ASSOCIATION; PREVALENCE; GUIDELINE; OVERDOSE; ONTARIO; MISUSE;
D O I
10.1016/j.drugalcdep.2021.108601
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Long-term prescription opioid use has been associated with adverse health outcomes, including opioid use disorder (OUD). We examined a population of opioid na?ve individuals who initiated prescription opioids for non-cancer pain and investigated the associations between opioid prescription characteristics at initiation and time to treated OUD. Methods: We conducted a retrospective population-based cohort study in Ontario, Canada among opioid na?ve individuals aged 15 years and older dispensed an opioid for non-cancer pain between 2013 and 2016. We used the Narcotic Monitoring System to abstract opioid dispensing data. A multivariable Cox regression model was used to examine the association between average daily dose and time to treated OUD. Results: We identified 1,607,659 opioid-na?ve individuals who initiated a prescription opioid within the study period. The incidence of treated OUD within the study period was 86 cases per 100,000 person-years. Compared to an average daily dose of <20 morphine milligrams equivalent (MME), higher average daily doses at initiation were associated with greater hazard of treated OUD, 20?50 MME (HR 1.11, 95% CI: 1.02, 1.21), >50-90 MME (HR 1.29, 95% CI: 1.16, 1.44), >90-150 MME (HR 1.29, 95% CI: 1.06, 1.56), >150?200 MME (HR 2.49, 95% CI: 1.54, 4.03) and >200 MME (HR 4.15, 95% CI: 2.89, 5.97). Long-acting formulations and days? supply ?11 days were also associated with greater hazard of treated OUD. Conclusion: Prescription opioid characteristics at initiation are associated with risk of treated OUD, identifying potentially important and modifiable risk factors among people initiating opioids for non-cancer pain.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study
    Wilton, James
    Abdia, Younathan
    Chong, Mei
    Karim, Mohammad Ehsanul
    Wong, Stanley
    MacInnes, Aaron
    Balshaw, Rob
    Zhao, Bin
    Gomes, Tara
    Yu, Amanda
    Alvarez, Maria
    Dart, Richard C.
    Krajden, Mel
    Buxton, Jane A.
    Janjua, Naveed Z.
    Purssell, Roy
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 375
  • [2] Opioid use disorder in patients with chronic non-cancer pain
    Brabant, Michel
    Brissette, Suzanne
    Lauzon, Pierre
    Marsan, Stephanie
    Ouellet-Plamondon, Clairelaine
    Pelletier, Marie-Chantal
    SANTE MENTALE AU QUEBEC, 2014, 39 (02): : 117 - 132
  • [3] Patients' Perspectives on the Development of Prescription Opioid Use Disorder in Patients with Chronic Non-Cancer Pain
    Davies, Lisa E. M.
    Koster, Ellen S. S.
    Damen, Katinka F. M.
    Beurmanjer, Harmen
    Schellekens, Arnt F. A.
    Bouvy, Marcel L. L.
    EUROPEAN ADDICTION RESEARCH, 2023, 29 (02) : 141 - 149
  • [4] Policies and Events Affecting Prescription Opioid Use for Non-Cancer Pain Among an Insured Patient Population
    Ahmedani, Brian K.
    Peterson, Edward L.
    Wells, Karen E.
    Lanfear, David E.
    Williams, L. Keoki
    PAIN PHYSICIAN, 2014, 17 (03) : 205 - 216
  • [5] Opioid use disorder in chronic non-cancer pain in Germany: a cross sectional study
    Just, Johannes Maximilian
    Schwerbrock, Fabian
    Bleckwenn, Markus
    Schnakenberg, Rieke
    Weckbecker, Klaus
    BMJ OPEN, 2019, 9 (04):
  • [6] Recent advances in opioid prescription for chronic non-cancer pain
    Snidvongs, Saowarat
    Mehta, Vivek
    POSTGRADUATE MEDICAL JOURNAL, 2012, 88 (1036) : 66 - 72
  • [7] FREQUENCY OF PRESCRIPTION OPIOID USE AND RISK FOR NEW ONSET DEPRESSION AMONG PATIENTS WITH NON-CANCER PAIN
    Scherrer, Jeffrey F.
    Salas, Joanne F.
    Sullivan, Mark
    Ballantyne, Jane
    Debar, Lynn
    Grucza, Richard F.
    Lustman, Patrick
    Ahmedani, Brian
    Miller-Matero, Lisa R.
    ANNALS OF BEHAVIORAL MEDICINE, 2022, 56 (SUPP 1) : S295 - S295
  • [8] Recommendations for safe opioid prescription in the management of chronic non-cancer pain
    Verastegui, Emma
    Plancarte, Ricardo
    Dominguez, Judith
    Burgos, Ruben
    Arrieta, Oscar
    Campillo, Carlos
    Angel Cells, Miguel
    De la-Llata, Manuel
    Halabe, Jose
    Islas, Sergio
    Jasso, Luis
    Lifshitz, Alberto
    Moreno, Mucio
    Reyes, Alejandro
    Ruiz-Arguelles, Guillermo
    Soda, Antonio
    Sotelo, Julio
    GACETA MEDICA DE MEXICO, 2018, 154 (04): : 532 - 533
  • [9] Prescription Opioid Initiation for Neuropathy, Headache, and Low Back Pain: A US Population-based Medicare Study
    Lin, Chun Chieh
    Callaghan, Brian C.
    Burke, James F.
    Kerber, Kevin A.
    Bicket, Mark C.
    Esper, Gregory J.
    Skolarus, Lesli E.
    Hill, Chloe E.
    JOURNAL OF PAIN, 2023, 24 (12): : 2268 - 2282
  • [10] Risk factors for long-term prescription opioid therapy for chronic non-cancer pain
    Hah, J.
    Zocca, J.
    Sharifzadeh, Y.
    Mackey, S.
    JOURNAL OF PAIN, 2016, 17 (04): : S10 - S11